Clinical Trial Update: A Safety and Efficacy Study of RX-0201 Plus Gemcitabine in Metastatic Pancreatic Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating RX-0201 in combination with gemcitabine for metastatic pancreatic cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Gemcitabine (Gemcitabine)
• RX-0201 (null)

Snippet

Sponsor: Rexahn Pharmaceuticals, Inc. | Conditions: Metastatic Pancreatic Cancer | Phase 2 | Status: COMPLETED